Oculis

Oculis

Oculis

Oculis is a clinical-stage, privately held, pharmaceutical development company focusing on ophthalmic drugs and novel drug delivery.
Type
B2b
Raised
$36M
Follow us
Alexa global traffic share
Latest funding Show all
$15,711,870
Venture capital (Series B) - 2019
Tekla Capital Management Nan Fung Life Sciences
$20,300,000
Venture capital (Series B) - 2018
Novartis Venture Fund Bay City Capital Brunnur Ventures +2
Team Size
1–10
Employees
Location
Headquarters
Silicon Canals

Swiss startup Oculis secures €13.8M funding to treat ophthalmic diseases

$15,711,870 Venture capital (Series B)
FinSMEs , PE HUB

Oculis Raises CHF15.5M in Extension of Series B Financing

PE HUB

| Oculis nabs $20.3 mln Series B

Funding Health
$20,300,000 Venture capital (Series B)
Norðurskautið , FinSMEs

Oculis raises $20.3m Series B round to advance treatment for Ophthalmic Diseases

Funding Health
Venture capital (Series A)
Norðurskautið

Oculis Pharma raises Series A led by Brunnur Ventures and Silfurberg

Health Funding